Patients who have been hospitalised with acute pancreatitis suspected to be related to glucagon-like peptide-1 receptor agonists (GLP-1 medicines), such as Ozempic and Mounjaro, are being asked to report it to the MHRAs Yellow Card scheme
After adjusting for covariates, poor glycemic control in T2DM patients was associated with a 29% higher risk of fractures compared to those with adequate glycemic control
It could be hypothesized that there is an association between the PK of the various GLP-1 RAs, the duration of receptor activation/occupancy and the extent of the HR effect
They provide several advantages, including: Lab-Tested Compounds: Xcel Peptides ensures that each batch of retatrutide is thoroughly tested by Janoshik Analytical laboratories
One possible issue of concern people with ME/CFS/FM is the possibility that carnitine may inhibit thyroid production
This blog explains how Ozempic and Mounjaro work, how they differ, who benefits most, and what to watch for during injection therapy
